No Data
No Data
Following the adoption of the initial public offering pre-purchase plan, Yimaikang (02192) issued 1.3095 million shares.
Yimeitong (02192) announced that on July 26, 2024, it acquired pre-emptive equity in connection with its initial public offering...
Medlinker (02192.HK) obtained the right to subscribe for 2.3733 million shares by purchasing equity.
On July 23rd, Gelonghui reported that Yimaitong (02192.HK) announced that it would issue 0.57325 million ordinary shares to the company's employees who exercised their pre-emption rights plan adopted by the company on March 29, 2021 on July 22, 2024. In addition, the company will issue 1.8 million ordinary shares to three directors who exercised their pre-emption rights plan adopted by the company on March 29, 2021 on July 22, 2024.
Medlive Technology Announces Secretary Change
Yang Yanling will independently serve as company secretary and authorized representative for iMedicine (02192.HK).
On July 15th, Gelonhui announced that Yang Yanling has been confirmed by the Stock Exchange to be qualified as the company secretary under Rule 3.28 of the Listing Rules. Therefore, Yang Yanling will independently serve as the company secretary and authorized representative from July 15, 2024. Ju Zhuoting has resigned as the joint company secretary and authorized representative of the company, effective from July 15, 2024. Ju Zhuoting will continue to serve as the legal process agent.
Are Medlive Technology Co., Ltd.'s (HKG:2192) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
There's Reason For Concern Over Medlive Technology Co., Ltd.'s (HKG:2192) Price
No Data
冷暖自知 : Very good return, long term or short term?